Cornea and External Disease

Longer-Term Data Reinforce Safety of Satralizumab in Neuromyelitis Optica Spectrum Disorder

Data from the 2 Phase 3 studies demonstrate satralizumab is well-tolerated in was well-tolerated in neuromyelitis optica spectrum disorder (NMOSD), including adolescents, according to a press release from Genentech. These data are being presented at the 6th Annual Meeting of the European Academy of Neurology. “The open-label extension data from the...